NCT06633536 - Real-life Treatment Outcomes of Ravulizumab in PNH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions

Paroxysmal Nocturnal Haemoglobinuria

Interventions

DRUG

Ravulizumab

open-label arm with ravulizumab administrated within the scope of routine clinical practice

Trial Locations (13)

RECRUITING

Research Site, Bialystok

RECRUITING

Research Site, Brzozów

RECRUITING

Research Site, Bydgoszcz

RECRUITING

Research Site, Gdansk

WITHDRAWN

Research Site, Katowice

RECRUITING

Research Site, Krakow

RECRUITING

Research Site, Lodz

RECRUITING

Research Site, Lublin

RECRUITING

Research Site, Opole

RECRUITING

Research Site, Szczecin

RECRUITING

Research Site, Warsaw

RECRUITING

Research Site, Wałbrzych

RECRUITING

Research Site, Wroclaw